110 related articles for article (PubMed ID: 17172705)
1. Druggable signaling proteins.
Sioud M; Leirdal M
Methods Mol Biol; 2007; 361():1-24. PubMed ID: 17172705
[TBL] [Abstract][Full Text] [Related]
2. Targeted cancer therapy: promise and reality.
Klein S; Levitzki A
Adv Cancer Res; 2007; 97():295-319. PubMed ID: 17419951
[TBL] [Abstract][Full Text] [Related]
3. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
4. EGFR signaling and drug discovery.
Lurje G; Lenz HJ
Oncology; 2009; 77(6):400-10. PubMed ID: 20130423
[TBL] [Abstract][Full Text] [Related]
5. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
Erman M
J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
[TBL] [Abstract][Full Text] [Related]
7. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
8. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
Buettner R; Mora LB; Jove R
Clin Cancer Res; 2002 Apr; 8(4):945-54. PubMed ID: 11948098
[TBL] [Abstract][Full Text] [Related]
9. A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways.
Tuck AB; Hota C; Wilson SM; Chambers AF
Oncogene; 2003 Feb; 22(8):1198-205. PubMed ID: 12606946
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
12. EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments.
Kataoka H
J Dermatol Sci; 2009 Dec; 56(3):148-53. PubMed ID: 19896805
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines.
Putz T; Culig Z; Eder IE; Nessler-Menardi C; Bartsch G; Grunicke H; Uberall F; Klocker H
Cancer Res; 1999 Jan; 59(1):227-33. PubMed ID: 9892211
[TBL] [Abstract][Full Text] [Related]
14. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of growth factor signalling.
Wakeling AE
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S183-7. PubMed ID: 16113095
[TBL] [Abstract][Full Text] [Related]
16. Anti-epidermal growth factor receptor strategies for advanced breast cancer.
Campos SM
Cancer Invest; 2008 Oct; 26(8):757-68. PubMed ID: 18853311
[No Abstract] [Full Text] [Related]
17. Epidermal growth factor receptor (EGFR) signaling in cancer.
Normanno N; De Luca A; Bianco C; Strizzi L; Mancino M; Maiello MR; Carotenuto A; De Feo G; Caponigro F; Salomon DS
Gene; 2006 Jan; 366(1):2-16. PubMed ID: 16377102
[TBL] [Abstract][Full Text] [Related]
18. STAT proteins: novel molecular targets for cancer drug discovery.
Turkson J; Jove R
Oncogene; 2000 Dec; 19(56):6613-26. PubMed ID: 11426647
[TBL] [Abstract][Full Text] [Related]
19. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
20. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
